CCR 20th Anniversary Commentary: RAS as a Biomarker for EGFR--Targeted Therapy for Colorectal Cancer-From Concept to Practice.
Clinical data support the use of EGFR mAbs in patients with metastatic colorectal cancer (mCRC) with wild-type RAS status. This notion, hypothesized in the review article by Camp, Ellis, and colleagues in the January 1, 2005, issue of Clinical Cancer Research, serves as an example of the successful application of basic science principles to clinical practice. The exclusion of patients with mCRC with Ras-mutated tumors from therapy with EGFR mAbs has led to improved outcomes while sparing patients unnecessary and potentially harmful therapy. See related article by Camp et al., Clin Cancer Res 2005;11(1): January 1, 2005;397-405.
Department of Surgery, Medical University of South Carolina, Charleston, South Carolina. Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina. Ralph H. Johnson VA Medical Center, Charleston, South Carolina.
E Ramsay
ER
Camp
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. lellis@mdanderson.org.
Lee M
LM
Ellis
D000846:Anniversaries and Special Events; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics; D000068818:Cetuximab / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics*; D006801:Humans; D018631:ras Proteins / Q000235:genetics*
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; C512478:EGFR protein, human; D066246:ErbB Receptors; D018631:ras Proteins; D000068818:Cetuximab